Amy has the ability to significantly impact our organization by combining her experience in bioanalytical operations and developing best in-class teams capable of supporting our industry's needs," stated John Bucksath CEO.
KANSAS CITY, Kan. (PRWEB) February 15, 2018
KCAS Bioanalytical and Biomarker Services, a leading functional service contract research organization (CRO) is pleased to announce the expansion of their executive leadership team. KCAS welcomes Amy Mize, Ph.D. to the position of Vice President of Business Development.
Dr. Amy Mize brings to KCAS critical skills in process development and implementation as well as sales and operation planning. She has built systems and processes around demand generation, capacity utilization and forecasting.
"Dr. Mize has been instrumental in growing organizations by developing teams who provide superior service and are committed to raising the bar to create a truly differentiating experience for pharma and CRO relationships. Her expertise in capacity planning, building superior sales and marketing teams and experience in operations management make her a key asset to KCAS' leadership team. Amy has the ability to significantly impact our organization by combining her experience in bioanalytical operations and developing best in-class teams capable of supporting our industry's needs," stated John Bucksath CEO.
Dr. Mize joins KCAS from EAG laboratories where she was the Vice President of Business Development and Commercial Operations. She received a B.S. in Chemistry from Baker University (Baldwin City, KS) and her Ph.D. in Pharmacology at the University of Kansas, Medical Center Campus. Amy completed her post-doctoral Fellowship at the University of Washington in Seattle.
"I am very excited to join the growing team at KCAS. The breadth of scientific expertise combined with the investments to the facility and equipment position the company for significant growth potential. I join a very talented team of Business Development professionals. Together, I am eager to focus on customer service, business processes and strategic initiatives as we continue to improve our forecasting and planning to ensure we provide our clients exceptional service," stated Amy Mize.
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 39+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS' team leverages a highly scientific staff with an average tenure in the field of bioanalysis/biomarker analysis of 22 years to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections. Learn more at: http://www.kcasbio.com